280 related articles for article (PubMed ID: 24755198)
21. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
22. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
23. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
24. Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas: Toward Genetic Distinctions of Animal-type Melanoma/Pigment Synthesizing Melanoma.
Cohen JN; Yeh I; Mully TW; LeBoit PE; McCalmont TH
Am J Surg Pathol; 2020 Jun; 44(6):805-816. PubMed ID: 32118628
[TBL] [Abstract][Full Text] [Related]
25. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
[TBL] [Abstract][Full Text] [Related]
26. The molecular profile of mucosal melanoma.
Mikkelsen LH; Maag E; Andersen MK; Kruhøffer M; Larsen AC; Melchior LC; Toft PB; von Buchwald C; Wadt K; Heegaard S
Melanoma Res; 2020 Dec; 30(6):533-542. PubMed ID: 33156594
[TBL] [Abstract][Full Text] [Related]
27. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso C
Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
[TBL] [Abstract][Full Text] [Related]
28. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
[TBL] [Abstract][Full Text] [Related]
29. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.
Lehmann BD; Shaver TM; Johnson DB; Li Z; Gonzalez-Ericsson PI; Sánchez V; Shyr Y; Sanders ME; Pietenpol JA
Mol Cancer Res; 2019 Sep; 17(9):1842-1853. PubMed ID: 31186280
[TBL] [Abstract][Full Text] [Related]
30. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
31. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
[TBL] [Abstract][Full Text] [Related]
32. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
Moon KR; Choi YD; Kim JM; Jin S; Shin MH; Shim HJ; Lee JB; Yun SJ
J Invest Dermatol; 2018 Apr; 138(4):933-945. PubMed ID: 29191620
[TBL] [Abstract][Full Text] [Related]
33. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
[TBL] [Abstract][Full Text] [Related]
34. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
36. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
37. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
38. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
39. The role of gene fusions in melanocytic neoplasms.
Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
[TBL] [Abstract][Full Text] [Related]
40. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
